tiprankstipranks
CVS Health Corp (MX:CVS)
NYSE:CVS
Mexico Market

CVS Health (CVS) Stock Forecast & Price Target

Followers
See the Price Targets and Ratings of:

CVS Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
CVS
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CVS Stock 12 Month Forecast

Average Price Target

$1,935.82
Based on 17 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is $1,935.82 with a high forecast of $2,153.59 and a low forecast of $1,610.81. The average price target represents a change from the last price of .
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1163":"$1,163","2154":"$2,154","1410.75":"$1,410.8","1658.5":"$1,658.5","1906.25":"$1,906.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2153.58756231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.15K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1935.821340308125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.94K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1610.81346124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.61K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1163,1410.75,1658.5,1906.25,2154],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1802.828,1829.809504793077,1856.791009586154,1883.7725143792309,1910.7540191723076,1937.7355239653846,1964.7170287584615,1991.6985335515385,2018.6800383446155,2045.6615431376924,2072.643047930769,2099.624552723846,2126.606057516923,{"y":2153.58756231,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1802.828,1813.0582569467788,1823.2885138935576,1833.5187708403364,1843.7490277871154,1853.9792847338942,1864.209541680673,1874.4397986274519,1884.6700555742307,1894.9003125210095,1905.1305694677885,1915.3608264145673,1925.5910833613461,{"y":1935.821340308125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1802.828,1788.0576508646154,1773.2873017292306,1758.516952593846,1743.7466034584615,1728.9762543230768,1714.2059051876922,1699.4355560523077,1684.6652069169231,1669.8948577815383,1655.1245086461538,1640.3541595107693,1625.5838103753845,{"y":1610.81346124,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1240.398,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1164.339,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1321.768,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1370.255,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1378.492,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1405.181,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1393.156,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1285.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1283.348,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1246.878,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1442.103,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1570.312,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1802.828,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,154Average Price Target$1,936Lowest Price Target$1,611
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$2,013.52$2,136.08
Buy
Reiterated
07/24/26
UBS Sticks to Its Buy Rating for CVS Health (CVS)
Wells Fargo Analyst forecast on MX:CVS
Wells Fargo
Wells Fargo
$2,153.59
Buy
Assigned
07/15/26
CVS Health price target raised to $123 from $103 at Wells FargoCVS Health price target raised to $123 from $103 at Wells Fargo
Truist Financial Analyst forecast on MX:CVS
Truist Financial
Truist Financial
$1,890.95$2,066.04
Buy
Reiterated
07/14/26
CVS Health price target raised to $118 from $108 at TruistCVS Health price target raised to $118 from $108 at Truist
Goldman Sachs Analyst forecast on MX:CVS
Goldman Sachs
Goldman Sachs
$1,820.92$2,031.03
Buy
Assigned
07/14/26
Goldman Sachs Sticks to Their Buy Rating for CVS Health (CVS)
Mizuho Securities Analyst forecast on MX:CVS
Mizuho Securities
Mizuho Securities
$2,013.52$2,101.06
Buy
Reiterated
07/13/26
Mizuho Securities Keeps Their Buy Rating on CVS Health (CVS)
RBC Capital Analyst forecast on MX:CVS
RBC Capital
RBC Capital
$1,873.45$1,978.5
Buy
Reiterated
07/09/26
CVS Health price target raised to $113 from $107 at RBC CapitalCVS Health price target raised to $113 from $107 at RBC Capital
Cantor Fitzgerald Analyst forecast on MX:CVS
Cantor Fitzgerald
Cantor Fitzgerald
$1,750.88$1,925.97
Buy
Reiterated
07/07/26
CVS Health price target raised to $110 from $100 at Cantor FitzgeraldCVS Health price target raised to $110 from $100 at Cantor Fitzgerald
HSBC
$1,488.25$1,803.41
Hold
Reiterated
07/06/26
CVS Health price target raised to $103 from $85 at HSBCCVS Health price target raised to $103 from $85 at HSBC
Bank of America Securities Analyst forecast on MX:CVS
Bank of America Securities
Bank of America Securities
$1,925.97
Buy
Reiterated
07/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on MX:CVS
Bernstein
Bernstein
$1,855.94
Buy
Reiterated
06/09/26
Bernstein Remains a Buy on CVS Health (CVS)
Morgan Stanley Analyst forecast on MX:CVS
Morgan Stanley
Morgan Stanley
$1,855.94$1,943.48
Buy
Reiterated
06/04/26
CVS Health price target raised to $111 from $106 at Morgan StanleyCVS Health price target raised to $111 from $106 at Morgan Stanley
J.P. Morgan Analyst forecast on MX:CVS
J.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Dexcom (NASDAQ: DXCM) and HCA Healthcare (NYSE: HCA)
Barclays
$1,768.39$1,855.94
Buy
Reiterated
05/26/26
CVS Health price target raised to $106 from $101 at BarclaysCVS Health price target raised to $106 from $101 at Barclays
Argus Research Analyst forecast on MX:CVS
Argus Research
Argus Research
$1,575.8$1,820.92
Buy
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), BioMarin Pharmaceutical (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)
TD Cowen
$1,838.43$1,925.97
Buy
Reiterated
05/11/26
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL) and CVS Health (NYSE: CVS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$2,013.52$2,136.08
Buy
Reiterated
07/24/26
UBS Sticks to Its Buy Rating for CVS Health (CVS)
Wells Fargo Analyst forecast on MX:CVS
Wells Fargo
Wells Fargo
$2,153.59
Buy
Assigned
07/15/26
CVS Health price target raised to $123 from $103 at Wells FargoCVS Health price target raised to $123 from $103 at Wells Fargo
Truist Financial Analyst forecast on MX:CVS
Truist Financial
Truist Financial
$1,890.95$2,066.04
Buy
Reiterated
07/14/26
CVS Health price target raised to $118 from $108 at TruistCVS Health price target raised to $118 from $108 at Truist
Goldman Sachs Analyst forecast on MX:CVS
Goldman Sachs
Goldman Sachs
$1,820.92$2,031.03
Buy
Assigned
07/14/26
Goldman Sachs Sticks to Their Buy Rating for CVS Health (CVS)
Mizuho Securities Analyst forecast on MX:CVS
Mizuho Securities
Mizuho Securities
$2,013.52$2,101.06
Buy
Reiterated
07/13/26
Mizuho Securities Keeps Their Buy Rating on CVS Health (CVS)
RBC Capital Analyst forecast on MX:CVS
RBC Capital
RBC Capital
$1,873.45$1,978.5
Buy
Reiterated
07/09/26
CVS Health price target raised to $113 from $107 at RBC CapitalCVS Health price target raised to $113 from $107 at RBC Capital
Cantor Fitzgerald Analyst forecast on MX:CVS
Cantor Fitzgerald
Cantor Fitzgerald
$1,750.88$1,925.97
Buy
Reiterated
07/07/26
CVS Health price target raised to $110 from $100 at Cantor FitzgeraldCVS Health price target raised to $110 from $100 at Cantor Fitzgerald
HSBC
$1,488.25$1,803.41
Hold
Reiterated
07/06/26
CVS Health price target raised to $103 from $85 at HSBCCVS Health price target raised to $103 from $85 at HSBC
Bank of America Securities Analyst forecast on MX:CVS
Bank of America Securities
Bank of America Securities
$1,925.97
Buy
Reiterated
07/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bernstein Analyst forecast on MX:CVS
Bernstein
Bernstein
$1,855.94
Buy
Reiterated
06/09/26
Bernstein Remains a Buy on CVS Health (CVS)
Morgan Stanley Analyst forecast on MX:CVS
Morgan Stanley
Morgan Stanley
$1,855.94$1,943.48
Buy
Reiterated
06/04/26
CVS Health price target raised to $111 from $106 at Morgan StanleyCVS Health price target raised to $111 from $106 at Morgan Stanley
J.P. Morgan Analyst forecast on MX:CVS
J.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), Dexcom (NASDAQ: DXCM) and HCA Healthcare (NYSE: HCA)
Barclays
$1,768.39$1,855.94
Buy
Reiterated
05/26/26
CVS Health price target raised to $106 from $101 at BarclaysCVS Health price target raised to $106 from $101 at Barclays
Argus Research Analyst forecast on MX:CVS
Argus Research
Argus Research
$1,575.8$1,820.92
Buy
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: CVS Health (NYSE: CVS), BioMarin Pharmaceutical (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)
TD Cowen
$1,838.43$1,925.97
Buy
Reiterated
05/11/26
Analysts Conflicted on These Healthcare Names: Agilon Health (NYSE: AGL) and CVS Health (NYSE: CVS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
GKOSGlaukos
ARDXArdelyx
STOKStoke Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVS Health

3 Months
Success Rate
16/24 ratings generated profit
67%
Average Return
+7.45%
Copying Elizabeth Anderson CFA's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +7.45% per trade.
1 Year
Allen LutzBank of America Securities
Success Rate
20/26 ratings generated profit
77%
Average Return
+24.60%
Copying Allen Lutz's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +24.60% per trade.
2 Years
Allen LutzBank of America Securities
Success Rate
26/26 ratings generated profit
100%
Average Return
+52.86%
Copying Allen Lutz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CVS Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
21
22
34
39
40
Hold
5
1
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
23
34
39
41
In the current month, CVS has received 40 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CVS average Analyst price target in the past 3 months is 1,935.82.
Each month's total comprises the sum of three months' worth of ratings.

CVS Financial Forecast

CVS Earnings Forecast

Next quarter’s earnings estimate for CVS is $32.37 with a range of $27.66 to $33.91. The previous quarter’s EPS was $45.00. CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.
Next quarter’s earnings estimate for CVS is $32.37 with a range of $27.66 to $33.91. The previous quarter’s EPS was $45.00. CVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.

CVS Sales Forecast

Next quarter’s sales forecast for CVS is $1.75T with a range of $1.71T to $1.84T. The previous quarter’s sales results were $1.76T. CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.
Next quarter’s sales forecast for CVS is $1.75T with a range of $1.71T to $1.84T. The previous quarter’s sales results were $1.76T. CVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year CVS has Performed in-line its overall industry.

CVS Stock Forecast FAQ

What is MX:CVS’s average 12-month price target, according to analysts?
Based on analyst ratings, CVS Health Corp’s 12-month average price target is 1,935.82.
    What is MX:CVS’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:CVS, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is CVS Health Corp a Buy, Sell or Hold?
        CVS Health Corp has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
          What is CVS Health Corp’s share price target?
          The average share price target for CVS Health Corp is 1,935.82. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $2,153.59 ,and the lowest forecast is $1,610.81. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about CVS Health Corp?
            CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
              How can I buy shares of CVS Health Corp?
              To buy shares of MX:CVS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.